We think Emmis faces several headwinds that will limit its long-term growth.
Somaxon has bet everything on Silenor for insomnia.
We are placing our fair value estimate for Spectrum Brands SPC under review as we assess the firm's announcement Monday that third-quarter results will be below expectations. At this point, management's credibility is completely spent. This warning joins a long list of others the firm has issued ...
Plus, a new Vanguard fund, changes at Fidelity, and more.